Journal of Clinical Pediatrics >
The treatment of ALPS-like with LRBA deficiency by haploid hematopoietic stem cell transplantation: a case report
Received date: 2024-04-23
Accepted date: 2024-07-24
Online published: 2025-05-09
A male infant, aged 1 month and 24 days, was diagnosed with immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). Whole-exome gene sequencing revealed compound heterozygous mutations of LRBA, confirming a diagnosis of LRBA deficiency with an ALPS-like phenotype. Despite treatments with corticosteroids, neonatal-like exchange transfusions, rituximab, and sirolimus, the ALPS-like symptoms persisted and were complicated by pulmonary infection and cytomegalovirus viremia. At 3 months of age, the patient underwent haploidentical hematopoietic stem cell transplantation (HSCT) using bone marrow from his father. Post-transplantation, successful engraftment of platelets and granulocytes was achieved, infections were controlled, and no severe complications occurred. Three months after transplantation, the infant developed grade Ⅱ skin graft-versus-host disease (GVHD), which resolved completely following treatment. Currently, more than 8 months after transplantation, the patient remains healthy with normalized immune function and no recurrence of the ALPS-like phenotype. This article retrospectively analyzed a case of a young patient with LRBA deficiency and an ALPS-like phenotype, evaluating the efficacy and safety of HSCT using bone marrow-derived hematopoietic stem cells from a haploidentical father. The study indicates that for children unresponsive to first-line treatments, HSCT should be considered as early as possible. In the absence of a fully matched donor, haploidentical donors and bone marrow-derived stem cells represent viable options that may enhance engraftment, reduce GVHD and infection risks, and improve transplantation outcomes. Further studies are required to optimize the treatment protocol and improve prognosis.
Key words: LRBA deficiency; ALPS-like; bone marrow transplantation; child
WANG Qingwei , ZHOU Min , CHENG Shengqin , XIAO Peifang , LU Jun , LI Jie , HU Shaoyan . The treatment of ALPS-like with LRBA deficiency by haploid hematopoietic stem cell transplantation: a case report[J]. Journal of Clinical Pediatrics, 2025 , 43(5) : 367 -370 . DOI: 10.12372/jcp.2025.24e0394
[1] | Lopez-Herrera G, Tampella G, Pan-Hammarstr?m Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity[J]. Am J Hum Genet, 2012, 90(6): 986-1001. |
[2] | Alangari A, Alsultan A, Adly N, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency[J]. J Allergy Clin Immunol, 2012, 130(2): 481-488. |
[3] | Alkhairy OK, Abolhassani H, Rezaei N, et al. Spectrum of phenotypes associated with mutations in LRBA[J]. J Clin Immunol, 2016, 36(1): 33-45. |
[4] | Habibi S, Zaki-Dizaji M, Rafiemanesh H, et al. Clinical, immunologic, and molecular spectrum of patients with LPS-responsive beige-like anchor protein deficiency: a systematic review[J]. J Allergy Clin Immunol Pract, 2019, 7(7): 2379-2386. |
[5] | Revel-Vilk S, Fischer U, Keller B, et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation[J]. Clin Immunol, 2015, 159(1): 84-92. |
[6] | Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States immune deficiency network registry[J]. J Allergy Clin Immunol, 2018, 141(3): 1028-1035. |
[7] | Riaz IB, Faridi W, Patnaik MM, et al. A systematic review on predisposition to lymphoid (B and T cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (inborn errors of immunity)[J]. Front Immunol, 2019, 10: 777. |
[8] | Seidel MG, B?hm K, Dogu F, et al. Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation[J]. J Allergy Clin Immunol, 2018, 141(2): 770-775. |
[9] | Tesch VK, Abolhassani H, Shadur B, et al. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score[J]. J Allergy Clin Immunol, 2020, 145(5): 1452-1463. |
[10] | Lo B, Zhang K, Lu W, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy[J]. Science, 2015, 349(6246): 436-440. |
[11] | Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis[J]. Blood, 2001, 98(1): 194-200. |
[12] | López-Nevado M, González-Granado LI, Ruiz-García R, et al. Primary immune regulatory disorders with an autoimmune lymphoproliferative syndrome-like phenotype: immunologic evaluation,early diagnosis and management[J]. Front Immunol, 2021, 12: 671755. |
[13] | Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome[J]. Br J Haematol, 2009, 145(1): 101-106. |
[14] | Azizi G, Abolhassani H, Zaki-Dizaji M, et al. Polyautoimmunity in patients with LPS-responsive beige-like anchor (LRBA) deficiency[J]. Immunol Invest, 2018, 47(5): 457-467. |
[15] | Kiykim A, Ogulur I, Dursun E, et al. Abatacept as a long-term targeted therapy for LRBA deficiency[J]. J Allergy Clin Immunol Pract, 2019, 7(8): 2790-2800. |
[16] | Taghizade N, Babayeva R, Kara A, et al. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency[J]. J Allergy Clin Immunol, 2023, 152(6): 1634-1645. |
[17] | Miyamoto S, Umeda K, Kurata M, et al. Hematopoietic cell transplantation for inborn errors of immunity other than severe combined immunodeficiency in Japan: retrospective analysis for 1985-2016[J]. J Clin Immunol, 2022, 42(3): 529-545. |
[18] | Lacan C, Lambert J, Forcade E, et al. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry[J]. J Hematol Oncol, 2024, 17(1): 2. |
/
〈 |
|
〉 |